OasisLMS

The CT Screening Symposium at WCLC 2026 is a 1-day, in-person event dedicated to advancing lung cancer screening and early detection through innovation, multidisciplinary collaboration, and global implementation strategies. The symposium will bring together international experts to discuss emerging evidence, evolving technologies, and practical approaches to optimizing lung cancer screening programs across diverse healthcare settings.

The program will feature four expert-led educational sessions during the morning, each followed by interactive panel discussions and audience Q+A. Topics will include the growing role of biomarkers in lung cancer screening and early detection, emerging evidence surrounding lung cancer screening in those who never smoked, the broader health benefits and incidental findings associated with low-dose CT screening, and the expanding use of artificial intelligence in lung cancer screening workflows and risk assessment.

Following the lunch break, attendees will return to the symposium for a hands-on, interactive workshop focused on practical and emerging challenges in lung cancer screening and early detection. Through multidisciplinary case-based discussions, participants will work through complex and challenging real-world screening scenarios, highlighting clinical decision-making, management considerations, and implementation challenges across diverse practice settings.

The workshop will also include expert debates on current controversies and hot topics within the field, encouraging audience engagement and discussion around evolving evidence, best practices, and future directions. Additional interactive components may include audience polling, multidisciplinary panel discussions, and problem-solving exercises designed to promote practical learning and peer-to-peer exchange.

Live Activity Date: September 12, 2026
Enduring Activity Launch Date: September 18, 2026
Enduring Activity Expiration Date: September 18, 2027

Radiologists, oncologists, pulmonologists, thoracic surgeons, radiologic technologists, researchers in the field of lung cancer, healthcare administrators, healthcare policy makers, and industry representatives involved in CT imaging and lung cancer diagnostics.

Learning objectives:

• Examine the current and emerging role of biomarkers in lung cancer screening and early detection, including their potential applications, limitations, and implementation challenges.
• Evaluate the evolving evidence surrounding lung cancer screening in people who never smoked, including potential benefits, harms, and future directions for risk stratification and screening eligibility.
• Analyze the broader health implications and additional clinical findings associated with lung cancer screening, including opportunities for detection and management.
• Illustrate the current and future applications of artificial intelligence in lung cancer screening and early detection, including imaging analysis, workflow optimization, and risk prediction.

Session Date & Time: 09/12/2026 08:00 AM - 09/12/2026 04:00 PM
Faculty:
- Mattias Johansson
- Harriet Lancaster
- Rayjean Hung
- Sebastian Schmidt
- Dawei Yang
- Pan-Chyr Yang
- Shira Boehler
- Kevin ten Haaf
- Yeon Wook Kim
- Martin Tammemagi
- Anna Kerpel-Fronius
- Annemiek Snoeckx
- Rozemarijn Vliegenthart
- Ella Kazerooni
- Marjolein Heuvelmans
- Jin Mo Goo
- Dorith Shaham
- Suresh Senan
- Natthaya Triphuridet
- Lucia Viola

WS02.01 - Talk 1: Foundations of Biomarker Research in Lung Cancer Screening
Session Date & Time: 09/12/2026 08:00 AM - 09/12/2026 04:00 PM
Faculty:
- Mattias Johansson

WS02.02 - Talk 2: Radiomics as an Imaging Biomarker
Session Date & Time: 09/12/2026 08:00 AM - 09/12/2026 04:00 PM
Faculty:
- Harriet Lancaster

WS02.03 - Talk 3: Protein Biomarkers in Lung Cancer Screening Program - Ready for Implementation?
Session Date & Time: 09/12/2026 08:00 AM - 09/12/2026 04:00 PM
Faculty:
- Rayjean Hung

WS02.04 - Talk 4: Challenges for the Implementation of Biomarkers into Lung Cancer Screening Programs
Session Date & Time: 09/12/2026 08:00 AM - 09/12/2026 04:00 PM
Faculty:
- Sebastian Schmidt

WS02.05 - Talk 1: Unmet Needs in Lung Cancer Screening for People who Never Smoked
Session Date & Time: 09/12/2026 08:00 AM - 09/12/2026 04:00 PM
Faculty:
- Dawei Yang

WS02.06 - Talk 2: Emerging Evidence for Screening Benefits in Low-Risk Populations/Those with No History of Smoking?
Session Date & Time: 09/12/2026 08:00 AM - 09/12/2026 04:00 PM
Faculty:
- Pan-Chyr Yang

WS02.07 - Talk 3: Expanding Early-Detection Policies and How We Define Risk
Session Date & Time: 09/12/2026 08:00 AM - 09/12/2026 04:00 PM
Faculty:
- Shira Boehler

WS02.08 - Talk 4: Considerations in the Trade-offs Between Benefits, Harms and Resource Requirements of Expanding Lung Cancer Screening to Low-risk Populations
Session Date & Time: 09/12/2026 08:00 AM - 09/12/2026 04:00 PM
Faculty:
- Kevin ten Haaf

WS02.09 - Talk 5: Future Directions in Risk Stratification and Research
Session Date & Time: 09/12/2026 08:00 AM - 09/12/2026 04:00 PM
Faculty:
- Yeon Wook Kim

WS02.10 - Talk 6: The Falcons Project - The IASLC Lung Cancer in Never Smokers Project
Session Date & Time: 09/12/2026 08:00 AM - 09/12/2026 04:00 PM

Talk 6: The Falcons Project - The IASLC Lung Cancer in Never Smokers Project
Session Date & Time: 09/12/2026 08:00 AM - 09/12/2026 04:00 PM
Faculty:
- Martin Tammemagi

WS02.11 - Talk 1: Beyond Lung Nodules - Understanding Incidental and Additional Findings
Session Date & Time: 09/12/2026 08:00 AM - 09/12/2026 04:00 PM
Faculty:
- Anna Kerpel-Fronius

WS02.12 - Talk 2: The BIG 3: Lung Cancer, COPD, and Cardiovascular Disease
Session Date & Time: 09/12/2026 08:00 AM - 09/12/2026 04:00 PM
Faculty:
- Annemiek Snoeckx

WS02.13 - Talk 3: Cardiovascular Disease in Screening CT
Session Date & Time: 09/12/2026 08:00 AM - 09/12/2026 04:00 PM
Faculty:
- Rozemarijn Vliegenthart

Talk 4: Emphysema and Other Findings
Session Date & Time: 09/12/2026 08:00 AM - 09/12/2026 04:00 PM
Faculty:
- Ella Kazerooni

WS02.15 - Talk 1: Quantification and Metrics in Thoracic CTs
Session Date & Time: 09/12/2026 08:00 AM - 09/12/2026 04:00 PM
Faculty:
- Ella Kazerooni

WS02.16 - Talk 2: AI for Lung Cancer Detection and Exclusion
Session Date & Time: 09/12/2026 08:00 AM - 09/12/2026 04:00 PM
Faculty:
- Marjolein Heuvelmans

WS02.17 - Talk 3: How AI Can Streamline Lung Cancer Screening Programs
Session Date & Time: 09/12/2026 08:00 AM - 09/12/2026 04:00 PM
Faculty:
- Jin Mo Goo

WS02.18 - Radiology Teaching Files and Self-Assessment Demo
Session Date & Time: 09/12/2026 08:00 AM - 09/12/2026 04:00 PM
Faculty:
- Dorith Shaham

Moderator: Case Reviews and Audience Engagement
Session Date & Time: 09/12/2026 08:00 AM - 09/12/2026 04:00 PM
Faculty:
- Suresh Senan

Case Reviews and Audience Engagement
Session Date & Time: 09/12/2026 08:00 AM - 09/12/2026 04:00 PM
Faculty:
- Natthaya Triphuridet

Case Reviews and Audience Engagement
Session Date & Time: 09/12/2026 08:00 AM - 09/12/2026 04:00 PM
Faculty:
- Dorith Shaham

Case Reviews and Audience Engagement
Session Date & Time: 09/12/2026 08:00 AM - 09/12/2026 04:00 PM
Faculty:
- Lucia Viola

Not for CME Credit

Accreditation Statement: 
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Association for the Study of Lung Cancer is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statements:

Physicians
The International Association for the Study of Lung Cancer designates the live and enduring activity for a maximum of 4.5 AMA PRA Category 1 Credits^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurse Practitioners and Registered Nurses
For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credit™ issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education).

Physician Associates
The National Commission on Certification of Physician Associates (NCCPA) states that the AMA PRA Category 1 Credits™ are acceptable for continuing medical education requirements for recertification.

Successful Completion
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

• 4.5 MOC point in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program; and
• 4.5 MOC point (Self Assessment) in the American Board of Thoracic Surgery (ABTS) Maintenance of Certification (MOC) program

It is the CME Activity provider's responsibility to submit participant completion information to ACCME for the purpose of recognizing participation. 

Countries that accept ACCME-accredited continuing medical education (CME):

The below list includes countries that accept ACCME-accredited continuing medical education (CME). Please note that some countries that accept ACCME-accredited education do not have specific credit requirements for their physicians. 

Antigua & Barbuda
Regulator: Antigua & Barbuda Medical Council

Austria
Regulator: Austrian Academy of Physicians on behalf of the Austrian Medical Chamber

Bahamas
Regulator: Bahamas Medical Council

Belgium
Regulator: Group of Belgian Professional Unions of Specialist Doctors

Bhutan
Regulator: Medical and Health Professional Council, Royal Government of Bhutan

Canada
Regulator: Royal College of Physicians and Surgeons of Canada Maintenance of Certification Program

Croatia
Regulator: Croatian Medical Chamber

Gambia, The
Regulator: The Medical and Dental Council of the Gambia

Germany
Regulator: State Chambers of Physicians in the 16 federal states (only in-person, live events)

India, State of Punjab
Regulator: Punjab Medical Council

Israel
Regulator: Scientific Council, Israeli Medical Association

Jamaica
Regulator: Medical Council of Jamaica

Kuwait
Regulator: Professional Licensing - Ministry of Health

Malawi
Regulator: Medical Council of Malawi

Netherlands, The
Regulator: Royal Dutch Society of the Promotion of Medicine

Oman
Regulator: Oman Medical Specialty Board

Qatar
Regulator: Accreditation Section of the Department of Healthcare Professions of the Qatar Ministry of Public Health

Rwanda
Regulator: Rwanda Medical & Dental Council

Saudi Arabia
Regulator: Saudi Commission for Health Specialties

Singapore
Regulator: Singapore Medical Council

South Africa
Regulator: Health Professions Council of South Africa

Spain
Regulator: Spanish Medical Professional Accreditation Council for CPD/CME

Sri Lanka
Regulator: Sri Lanka Medical Council, Sri Lanka Medical Association, and the Ministry of Health

Sweden
Regulator: Swedish Medical Association

Trinidad & Tobago
Regulator: The Trinidad and Tobago Medical Association

Turkey
Regulator: Turkish Medical Association CME-CPD Accreditation Council

United Arab Emirates, Abu Dhabi
Regulator: Department of Health

United Arab Emirates, Dubai
Regulator: Dubai Health Authority

The information presented is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

Enduring Activity Credit

This activity is designed to be completed within the time designated on the title page; participants should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must complete the evaluation and post-survey. Follow these steps to earn CME/CE credit*:

1. Read about the target audience, learning objectives, and author disclosures.
2. Study the educational content online or print it out, if applicable.
3. Complete the activity evaluation to provide feedback for future programming and receive credit.
4. Complete the post-survey within the required time period.

You may now view or print the certificate from your CME/CE Transcript. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Transcript and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Transcript.

*The credit that you receive is based on your membership profile.

If you need any assistance with this activity, please email: education@iaslc.org.